Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics ...

Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track ...

Projected to be worth over $38 billion in the global healthcare market by 2032, AI simulations have the potential to ...

Trump is rounding out his health cabinet with another controversial figure: one of the authors of the Great Barrington ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated ...

Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...

The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

Career conservative and former congressman Dave Weldon will, if confirmed, act as director of the Centers of Disease Control ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...